Current Cardiology Reports

, 2:395

Novel inhibitors of factor X for use in cardiovascular diseases

  • Frederick A. Spencer
  • Richard C. Becker
Article

Abstract

The complementary roles of platelets and thrombin in the pathophysiology of acute coronary syndromes suggests that for treatment to be effective, both mediators must be targeted. Although great strides have been made in the development of antiplatelet therapies, attempts to inhibit thrombin have been less successful. Unfractionated heparin is limited by a number of pharmacologic shortcomings as well as an inability to meaningfully suppress thrombin generation. The low molecular weight heparins have yielded encouraging results in large-scale clinical trials, but it remains unclear whether their benefit stems from a superior pharmacologic profile to unfractionated heparin or is determined by an enhanced ability to suppress thrombin generation (by virtue of a direct anti-Xa effect). Regardless, investigators have become increasingly interested in factor Xa as a potential target for antithrombotic therapy. A number of naturally occurring Xa antagonists have been identified. Work with recombinant forms of these proteins confirms that factor Xa inhibition can suppress thrombin generation in a variety of animal thrombosis models. Accordingly, a number of synthetic direct and indirect Xa antagonists are under development for the prevention and treatment of thrombotic disorders. The following review summarizes the evolution of factor Xa antagonists.

References and Recommended Reading

  1. 1.
    Oler A, Whooley MA, Oler J, Grady D: Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. JAMA 1996, 276:811–815.PubMedCrossRefGoogle Scholar
  2. 2.
    Spencer FA, Ball SP, Zhang Q, et al.: Enoxaparin, a low molecular weight heparin, inhibits platelet-dependent prothrombinase assembly and activity by Factor-Xa neutralization. J Thromb Thrombolysis 2000, 9:223–228.In this laboratory investigation plasma from patients administered enoxaparin (in TIMI-11B) inhibits prothrombinase assembly and activity in vitro. This suggests enoxaparin’s anti Xa effect is, in fact, critical to its antithrombotic efficacy.PubMedCrossRefGoogle Scholar
  3. 3.
    Ellis V, Scully ME, Kakkar VV: Inhibition of prothrombinase complex by plasma proteinase inhibitors. Biochemistry 1984, 23:5882–5887.PubMedCrossRefGoogle Scholar
  4. 4.
    Barrowcliffe TW, Havercroft SJ, Kemball-Cook G, Lindahl U: The effect of Ca2+, phospholipid, and factor V on the anti-(factor Xa) activity of heparin and its high affinity oligosaccharides. Biochem J 1987, 243:31–37.PubMedGoogle Scholar
  5. 5.
    Cohen M, Demers C, Gurfinkel EP, et al.: A comparison of low molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997, 337:447–452.PubMedCrossRefGoogle Scholar
  6. 6.
    Antman EM, McCabe CH, Gurfinkel EP, et al.: Enoxaparin prevents death and cardiac ischemic events in unstable Angina/Non-Q-wave myocardial infarction: results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation 1999, 100:1593–601.PubMedGoogle Scholar
  7. 7.
    Fragmin during Instability in Coronary Artery Disease (FRISC) study group: Low-molecular-weight heparin during instability in coronary artery disease. Lancet 1996, 347:561–568.Google Scholar
  8. 8.
    Choay J, Petitou M, Lormeau JC, et al.: Structure-activity relationship in heparin: a synthetic pentasaccharide with high affinity for antithrombin III and eliciting high antifactor Xa activity. Biochem Biophys Res Commun 1983, 116:492–499.PubMedCrossRefGoogle Scholar
  9. 9.
    Cadroy Y, Hanson SR, Harker LA: Antithrombotic effects of synthetic pentasaccharide with high affinity for plasma antithormbin III in non-human primates. Thromb Haemost 1993, 70:631–635.PubMedGoogle Scholar
  10. 10.
    Herbert JM, Herault JP, Bernat A, et al.: Biochemical and pharmacological properties of SANORG 32701. Comparison with the "synthetic pentasaccharide" (SR 90107/ORG 31540) and standard heparin Circ Res 1996, 79:590–600.PubMedGoogle Scholar
  11. 11.
    Pislaru SV, Pislaru C, Zhu X, et al.: Comparison of a synthetic antithrombin III-binding pentasaccharide and standard heparin as an adjunct to coronary thrombolysis. Thromb Haemost 1998, 79:1130–1135.PubMedGoogle Scholar
  12. 12.
    Boneu B, Necciari J, Cariou R, et al.: Pharmacokinetics and tolerance of the natural pentasaccharide (SR90107/ORG 31540) with high affinity to antithrombin III in man. Thromb Haemost 1995, 74:1468–1473.PubMedGoogle Scholar
  13. 13.
    Verstraete M: New developments in antiplatelet and antithrombotic therapy. Eur Heart J 1995, 16(Suppl L):16–23.PubMedGoogle Scholar
  14. 14.
    Vuillemenot A, Schiele F, Memeveau N, et al.: Efficacy of a synthetic pentasaccharide, a pure factor Xa inhibitor, as an antithrombotic agent-a pilot study in the setting of coronary angioplasty. Thromb Haemost 1999, 81:214–220. One of the first human clinical trials evaluating a direct Xa inhibitor. Suggests synthetic pentasaccharide is a safe antithrombotic agent for use during elective angioplasty.PubMedGoogle Scholar
  15. 15.
    Coussement PK: SR9010A/ORG31540, a new synthetic pentasaccharide, as an adjunct to fibrinolysis in ST-elevation acute myocardial infarction: the PENTALYSE Study. Presented to the ACC Scientific Session 2000. March 15, 2000.Google Scholar
  16. 16.
    Herbert JM, Hérault JP, Bernat A, et al.: Biochemical and pharmacological properties of SANORG 32701: comparison with the "synthetic pentasaccharide" (SR 90107/ORG 31540) and standard heparin. Circ Res 1996, 79:590–600.PubMedGoogle Scholar
  17. 17.
    Herbert JM, Hérault JP, Bernat A, et al.: Biochemical and pharmacological properties of SANORG 34006, a potent and long-acting synthetic pentasaccharide. Blood 1998, 91:4197–4205.PubMedGoogle Scholar
  18. 18.
    Bagdy D, Barabas É, Gràf L, et al.: Hirudin. Methods Enzymol 1976, 45:669–678.PubMedCrossRefGoogle Scholar
  19. 19.
    Seemuller U, Meier M, Ohlsson K, et al.: Isolation and characterization of a low molecular weight inhibitor (of chymotrypsin and human granulocytic elastase and cathepsin G) from leeches. Hoppe-Seylers Zeitschrift fur Physiol Chem 1977, 358:1105–1117.Google Scholar
  20. 20.
    Malinconico SM, Katz JB, Budzynski AZ: Hementin — anticoagulant protease from the salivary gland of the leech Haementeria ghilaranii. J Lab Clin Med 1984, 103:44–58.PubMedGoogle Scholar
  21. 21.
    Kelen EMA, Rosenfeld G: Fibrinogenolytic substance (hementerin) of Brazilian blood-sucking leeches (Haementeria lutzi Pinto 1920) Haemostasis 1975, 4:51–64.PubMedGoogle Scholar
  22. 22.
    Tuszynski GP, Gasic TB, Gasic GJ: Isolation and characterization of antistasin: an inhibitor of metastasis and coagulation. J Biol Chem 1987, 262:9718–9723.PubMedGoogle Scholar
  23. 23.
    Dunwiddie C, Thornberry NA, Bull HG, et al.: Antistasin, a leech-derived inhibitor of factor Xa: kinetic analysis of enzyme inhibition and identification of the reactive site. J Biol Chem 1989, 264:16694–16699.PubMedGoogle Scholar
  24. 24.
    Nutt EM, Jain D, Lenny AB, et al.: Purification and characterization of recombinant antistasin: a leech-derived inhibitor of coagulation factor Xa. Arch Biochem Biophys 1991, 285:37–44.PubMedCrossRefGoogle Scholar
  25. 25.
    Schaffer LW, Davidson JT, Vlasuk GP, et al.: Selective factor Xa inhibition by recombinant antistasin prevents vascular graft thrombosis in baboons. Arterioscler Thromb 1992, 12:879–885.PubMedGoogle Scholar
  26. 26.
    Mellott MJ, Holahan MA, Lynch JJ, et al.: Acceleration of recombinant tissue-type plasminogen activator-induced reperfusion and prevention of reocclusion by recombinant antistasin, a selective factor Xa inhibitor, in a canine model of femoral arterial thrombosis. Circ Res 1992, 70:1152–1160.PubMedGoogle Scholar
  27. 27.
    Dunwiddie CT, Nutt EM, Vlasuk GP, et al.: Anticoagulant efficacy and immunogenicity of the selective factor Xa inhibitor antistasin following subcutaneous administration in the rhesus monkey. Thromb Haemost 1992, 67:371–376.PubMedGoogle Scholar
  28. 28.
    Waxman L, Smith DE, Arcuri KE, Vlasuk GP: Tick anticoagulant peptide (TAP) is a novel inhibitor of blood coagulation factor Xa. Science 1990, 248:593–596.PubMedCrossRefGoogle Scholar
  29. 29.
    Lehman ED, Schaefer TF, Przysiecki CT, et al.: Large scale purification and characterization of recombinant tick anticoagulant peptide. J Chromatog 1992, 574:225–235.CrossRefGoogle Scholar
  30. 30.
    Schaffer LW, Davidson JT, Vlasuk GP, Siegl PKS: Antithrombotic efficacy of recombinant tick anticoagulant peptide: a potent inhibitor of coagulation factor Xa in a primate model of arterial thrombosis. Circulation 1991, 84:1741–1748.PubMedGoogle Scholar
  31. 31.
    Sitko GR, Ramjit DR, Stabilito II, et al.: Conjunctive enhancement of enzymatic thrombolysis and prevention of thrombotic reocclusion with the selective factor Xa inhibitor, tick anticoagulant peptide: comparison to hirudin and heparin in a canine model of acute coronary artery thrombosis. Circulation 1992, 85:805–815.PubMedGoogle Scholar
  32. 32.
    Lynch Jr JJ, Sitko GR, Lehman ED, Vlasuk GP: Primary prevention of coronary arterial thrombosis with the factor Xa inhibitor rTAP in a canine electrolytic injury model. Thromb Haemost 1995, 74:640–645.PubMedGoogle Scholar
  33. 33.
    Cappello M, Vlasuk GP, Bergum PW, Huang S, Hotez PJ: Ancylostoma caninum anticoagulant peptide: a hookwormderived inhibitor of human coagulation factor Xa. Proc Natl Acad Sci U S A 1995, 92:6152–6156.PubMedCrossRefGoogle Scholar
  34. 34.
    Stanssens P, Bergum PW, Gansemans Y, et al.: Anticoagulant repertoire of the hookworm Ancylostoma canium. Proc Natl Acad Sci U S A 1996, 93:2149–2154.CrossRefGoogle Scholar
  35. 35.
    Rote WE, Vlasuk GP: Evaluation of a novel small protein inhibitor of blood coagulation factor Xa in a porcine model of acute coronary artery thrombosis. Circulation 1995, 92(Suppl 1):2322.Google Scholar
  36. 36.
    Rebello SS, Blank HS, Rote WE, et al.: Antithrombotic efficacy of a recombinant nematode anticoagulant peptide (rNAP5) in canine models of thrombosis after single subcutaneous administration. J Pharmacol Exp Ther 1997, 283:91–99.PubMedGoogle Scholar
  37. 37.
    Hara T, Yokoyama A, Ishihara H, et al.: DX-9065a, a new synthetic, potent anticoagulant and selective inhibitor for factor Xa. Thromb Haemost 1994, 41:314–319.Google Scholar
  38. 38.
    Hara T, Yokoyama A, Tanabe K, et al.: DX-9065a, an orally active, specific inhibitor of factor Xa, inhibits thrombosis without affecting bleeding time in rats. Thromb Haemost 1995, 74:635–639.PubMedGoogle Scholar
  39. 39.
    Morishima Y, Tanabe K, Terada Y, et al.: Antithrombotic and hemorrhagic effects of DX-9065a, a direct and selective factor Xa inhibitor: comparison with a direct thrombin inhibitor and antithrombin III-dependent anticoagulants. Thromb Haemost 1997, 78:1366–1371.PubMedGoogle Scholar
  40. 40.
    Wong PC, Crain Jr EJ, Nguan O, et al.: Antithrombotic actions of selective inhibitors of blood coagulation factor Xa in rat models of thrombosis. Thromb Res 1996, 83:117–126.PubMedCrossRefGoogle Scholar
  41. 41.
    Rogers KL, Chi L, Rapundalo ST, et al.: Effects of a factor Xa inhibitor, DX-9065a, in a novel rabbit model of venous thrombosis. Basic Res Cardiol 1999, 94:15–22.PubMedCrossRefGoogle Scholar
  42. 42.
    Yokoyama T, Kelly AB, Marzec UM, et al.: Antithrombotic effects of orally active synthetic antagonist of activated factor X in nonhuman primates. Circulation 1995, 92:485–491.PubMedGoogle Scholar
  43. 43.
    Murayama N, Tanaka M, Kunitada S, et al.: Tolerability, pharmacokinetics, and pharmacodynamics of DX-9065a, a new synthetic potent anticoagulant and specific factor Xa inhibitor, in healthy male volunteers. Clin Pharmacol Therapy 1999, 66:258–264. One of the first published reports of the pharmacokinetics and pharmacodynamics of a synthetic direct Xa antagonist in human subjects.CrossRefGoogle Scholar
  44. 44.
    Taniuchi Y, Sakai Y, Hisamichi N, et al.: Biochemical and pharmacological characterization of YM-60828, a newly synthesized and orally active inhibitor of human factor Xa. Thromb Haemost 1998, 79:543–548.PubMedGoogle Scholar
  45. 45.
    Sato K, Kawasaki T, Hisamichi N, et al.: Antithrombotic effects of YM-60828, a newly synthesized factor Xa inhibitor, in rat thrombosis models and its effects on bleeding time Brit J Pharmacol 1998, 123:92–96.CrossRefGoogle Scholar
  46. 46.
    Sato K, Kawasaki T, Taniuchi Y, et al.: YM-60828, a novel factor Xa inhibitor: separation of its antithrombotic effects from its prolongation of bleeding time. Eur J Pharmacol 1997, 339:141–146.PubMedCrossRefGoogle Scholar
  47. 47.
    Sato K, Kawasaki T, Hisamichi N, et al.: Antithrombotic effects of YM-60828 in three thrombosis models in guinea pigs (short commun.) Eur J Pharmacol 1998, 350:87–91.PubMedCrossRefGoogle Scholar
  48. 48.
    Kawasaki T, Sato K, Sakai Y, et al.: Comparative studies of an orally-active factor Xa inhibitor, YM-60828, with other antithrombotic agents in a rat model of arterial thrombosis. Thromb Haemost 1998, 79:410–416. Early work with a new synthetic Xa antagonist. In a rat model of carotid thrombosis YM-60828 significantly and dose-dependently increased carotid patency compared with a variety of other commonly used antithrombotic agents.PubMedGoogle Scholar
  49. 49.
    Kawasaki T, Sato K, Hirayama F, et al.: Effect of a synthetic factor Xa inhibitor, YM-60828, on blood vessel patency in combination with a thrombolytic agent and on blood loss from the operation site in a rat model of arterial thrombosis Thromb Haemost 1998, 79:859–64.PubMedGoogle Scholar
  50. 50.
    Sato K, Taniuchi Y, Kawasaki T, et al.: Comparison of the anticoagulant and antithrombotic effects of YM-75466, a novel orally-active factor Xa inhibitor, and warfarin in mice. Jpn J Pharmacol 1998, 78:191–197.PubMedCrossRefGoogle Scholar
  51. 51.
    Sato K, Taniuchi Y, Kawasaki T, et al.: Relationship between the antithrombotic effect of YM-75466, a novel factor Xa inhibitor, and coagulation parameters in rats. Eur J Pharmacol 1998, 347:231–236.PubMedCrossRefGoogle Scholar
  52. 52.
    Sato K, Kaku S, Hirayama F, et al.: Antithrombotic effect of YM-75466 is separated from its effect on bleeding time and coagulation time. Eur J Pharmacol 1998, 352:59–63.PubMedCrossRefGoogle Scholar
  53. 53.
    Quan ML, Pruitt JR, Ellis CD, et al.: Bisbenzamidine isoxazoline derivatives as factor Xa inhibitors. Bioorg Med Chem Lett 1997, 7:2813–2818.CrossRefGoogle Scholar
  54. 54.
    Quan ML, Ellis CD, Liauw AY, et al.: Design and synthesis of isoxazoline derivatives as factor Xa inhibitors.2. J Med Chem 1999a, 42:2760–2773.CrossRefGoogle Scholar
  55. 55.
    Quan ML, Liauw AY, Ellis CD, et al.: Design and synthesis of isoxazoline derivatives as factor Xa inhibitors.1. J Med Chem 1999b, 42:2752–2759.CrossRefGoogle Scholar
  56. 56.
    Wong PC, Quan ML, Crain EJ, et al.: Nonpeptide factor Xa inhibitors: I. Studies with SF303 and SK549, a new class of potent antithrombotics. J Pharmacol Exp Ther 2000, 292:351–357. A description of early animal studies of the antithrombotic efficacy of a new class of Xa antagonists bearing some structural similarities to GP IIb/IIIa antagonists. In these studies, SF-303 and SK-549 were of comparable potency to other Xa antagonists and were much more potent antithrombotics than UH or LMWH.PubMedGoogle Scholar

Copyright information

© Current Science Inc 2000

Authors and Affiliations

  • Frederick A. Spencer
    • 1
  • Richard C. Becker
    • 1
  1. 1.Cardiovascular Thrombosis Research CenterUMass Memorial Medical CenterWorcesterUSA

Personalised recommendations